These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38575671)

  • 81. TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target.
    Kennedy E; Coulter E; Halliwell E; Profitos-Peleja N; Walsby E; Clark B; Phillips EH; Burley TA; Mitchell S; Devereux S; Fegan CD; Jones CI; Johnston R; Chevassut T; Schulz R; Seiffert M; Agathanggelou A; Oldreive C; Davies N; Stankovic T; Liloglou T; Pepper C; Pepper AGS
    Blood; 2021 Jun; 137(22):3064-3078. PubMed ID: 33512408
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Screening and monitoring of the BTK
    Bödör C; Kotmayer L; László T; Takács F; Barna G; Kiss R; Sebestyén E; Nagy T; Hegyi LL; Mikala G; Fekete S; Farkas P; Balogh A; Masszi T; Demeter J; Weisinger J; Alizadeh H; Kajtár B; Kohl Z; Szász R; Gergely L; Gurbity Pálfi T; Sulák A; Kollár B; Egyed M; Plander M; Rejtő L; Szerafin L; Ilonczai P; Tamáska P; Pettendi P; Lévai D; Schneider T; Sebestyén A; Csermely P; Matolcsy A; Mátrai Z; Alpár D
    Br J Haematol; 2021 Jul; 194(2):355-364. PubMed ID: 34019713
    [TBL] [Abstract][Full Text] [Related]  

  • 83. DAP Kinase-Related Apoptosis-Inducing Protein Kinase 2 (DRAK2) Is a Key Regulator and Molecular Marker in Chronic Lymphocytic Leukemia.
    Szoltysek K; Ciardullo C; Zhou P; Walaszczyk A; Willmore E; Rand V; Marshall S; Hall A; J Harrison C; Eswaran J; Soundararajan M
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081245
    [TBL] [Abstract][Full Text] [Related]  

  • 84. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway.
    Endo T; Nishio M; Enzler T; Cottam HB; Fukuda T; James DF; Karin M; Kipps TJ
    Blood; 2007 Jan; 109(2):703-10. PubMed ID: 16973958
    [TBL] [Abstract][Full Text] [Related]  

  • 85. S100-A9 protein in exosomes from chronic lymphocytic leukemia cells promotes NF-κB activity during disease progression.
    Prieto D; Sotelo N; Seija N; Sernbo S; Abreu C; Durán R; Gil M; Sicco E; Irigoin V; Oliver C; Landoni AI; Gabus R; Dighiero G; Oppezzo P
    Blood; 2017 Aug; 130(6):777-788. PubMed ID: 28596424
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia.
    Del Papa B; Baldoni S; Dorillo E; De Falco F; Rompietti C; Cecchini D; Cantelmi MG; Sorcini D; Nogarotto M; Adamo FM; Mezzasoma F; Silva Barcelos EC; Albi E; Iacucci Ostini R; Di Tommaso A; Marra A; Montanaro G; Martelli MP; Falzetti F; Di Ianni M; Rosati E; Sportoletti P
    Clin Cancer Res; 2019 Dec; 25(24):7540-7553. PubMed ID: 31578228
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Ibrutinib combinations in CLL therapy: scientific rationale and clinical results.
    Timofeeva N; Gandhi V
    Blood Cancer J; 2021 Apr; 11(4):79. PubMed ID: 33927183
    [TBL] [Abstract][Full Text] [Related]  

  • 88. STAT-3 activates NF-kappaB in chronic lymphocytic leukemia cells.
    Liu Z; Hazan-Halevy I; Harris DM; Li P; Ferrajoli A; Faderl S; Keating MJ; Estrov Z
    Mol Cancer Res; 2011 Apr; 9(4):507-15. PubMed ID: 21364020
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia.
    Knittel G; Rehkämper T; Korovkina D; Liedgens P; Fritz C; Torgovnick A; Al-Baldawi Y; Al-Maarri M; Cun Y; Fedorchenko O; Riabinska A; Beleggia F; Nguyen PH; Wunderlich FT; Ortmann M; Montesinos-Rongen M; Tausch E; Stilgenbauer S; P Frenzel L; Herling M; Herling C; Bahlo J; Hallek M; Peifer M; Buettner R; Persigehl T; Reinhardt HC
    Nat Commun; 2017 Jul; 8(1):153. PubMed ID: 28751718
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia.
    Zhang Y; Zhou X; Li Y; Xu Y; Lu K; Li P; Wang X
    Oncogene; 2018 Oct; 37(41):5520-5533. PubMed ID: 29895969
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Induction of endothelial cell proliferation and von Willebrand factor expression and secretion by leukemic plasma of patients with chronic lymphocytic leukemia before and after inhibition of NF-κB.
    Shahidi M; Mohsen Razavi S; Hayat P
    Blood Coagul Fibrinolysis; 2016 Sep; 27(6):711-6. PubMed ID: 27472040
    [TBL] [Abstract][Full Text] [Related]  

  • 92. A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.
    Wiśniewski K; Puła B
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791284
    [TBL] [Abstract][Full Text] [Related]  

  • 93. HuR Affects Proliferation and Apoptosis of Chronic Lymphocytic Leukemia Cells via NF-
    Xiao K; Yang L; Gao X; An Y; Xie W; Jingquan G
    Biomed Res Int; 2020; 2020():1481572. PubMed ID: 32908868
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells.
    Liang X; Moseman EA; Farrar MA; Bachanova V; Weisdorf DJ; Blazar BR; Chen W
    Blood; 2010 Jun; 115(24):5041-52. PubMed ID: 20339095
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation.
    Yeomans A; Thirdborough SM; Valle-Argos B; Linley A; Krysov S; Hidalgo MS; Leonard E; Ishfaq M; Wagner SD; Willis AE; Steele AJ; Stevenson FK; Forconi F; Coldwell MJ; Packham G
    Blood; 2016 Jan; 127(4):449-57. PubMed ID: 26491071
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment.
    Guo A; Lu P; Coffey G; Conley P; Pandey A; Wang YL
    Oncotarget; 2017 Feb; 8(8):12953-12967. PubMed ID: 28088788
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.
    Reiff SD; Muhowski EM; Guinn D; Lehman A; Fabian CA; Cheney C; Mantel R; Smith L; Johnson AJ; Young WB; Johnson AR; Liu L; Byrd JC; Woyach JA
    Blood; 2018 Sep; 132(10):1039-1049. PubMed ID: 30018078
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia.
    Chen Y; Chen L; Yu J; Ghia EM; Choi MY; Zhang L; Zhang S; Sanchez-Lopez E; Widhopf GF; Messer K; Rassenti LZ; Jamieson C; Kipps TJ
    Blood; 2019 Sep; 134(13):1084-1094. PubMed ID: 31409670
    [TBL] [Abstract][Full Text] [Related]  

  • 99. mTORC1-selective activation of translation elongation promotes disease progression in chronic lymphocytic leukemia.
    Malik N; Hay J; Almuhanna HNB; Dunn KM; Lees J; Cassels J; Li J; Nakagawa R; Sansom OJ; Michie AM
    Leukemia; 2023 Dec; 37(12):2414-2425. PubMed ID: 37775560
    [TBL] [Abstract][Full Text] [Related]  

  • 100. IκBε deficiency accelerates disease development in chronic lymphocytic leukemia.
    Bordini J; Lenzi C; Frenquelli M; Morabito A; Pseftogas A; Belloni D; Mansouri L; Tsiolas G; Perotta E; Ranghetti P; Gandini F; Genova F; Hägerstrand D; Gavriilidis G; Keisaris S; Pechlivanis N; Davi F; Kay NE; Langerak AW; Pospisilova S; Scarfò L; Makris A; Psomopoulos FE; Stamatopoulos K; Rosenquist R; Campanella A; Ghia P
    Leukemia; 2024 Jun; 38(6):1287-1298. PubMed ID: 38575671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.